Literature DB >> 24503136

The Pex1-G844D mouse: a model for mild human Zellweger spectrum disorder.

Shandi Hiebler1, Tomohiro Masuda2, Joseph G Hacia3, Ann B Moser1,4, Phyllis L Faust5, Anita Liu1, Nivedita Chowdhury1, Ning Huang3, Amanda Lauer6, Jean Bennett7, Paul A Watkins1,4, Donald J Zack2,8,9,10, Nancy E Braverman11,12, Gerald V Raymond1,4, Steven J Steinberg1,4,8.   

Abstract

Zellweger spectrum disorder (ZSD) is a disease continuum that results from inherited defects in PEX genes essential for normal peroxisome assembly. These autosomal recessive disorders impact brain development and also cause postnatal liver, adrenal, and kidney dysfunction, as well as loss of vision and hearing. The hypomorphic PEX1-G843D missense allele, observed in approximately 30% of ZSD patients, is associated with milder clinical and biochemical phenotypes, with some homozygous individuals surviving into early adulthood. Nonetheless, affected children with the PEX1-G843D allele have intellectual disability, failure to thrive, and significant sensory deficits. To enhance our ability to test candidate therapies that improve human PEX1-G843D function, we created the novel Pex1-G844D knock-in mouse model that represents the murine equivalent of the common human mutation. We show that Pex1-G844D homozygous mice recapitulate many classic features of mild ZSD cases, including growth retardation and fatty livers with cholestasis. In addition, electrophysiology, histology, and gene expression studies provide evidence that these animals develop a retinopathy similar to that observed in human patients, with evidence of cone photoreceptor cell death. Similar to skin fibroblasts obtained from ZSD patients with a PEX1-G843D allele, we demonstrate that murine cells homozygous for the Pex1-G844D allele respond to chaperone-like compounds, which normalizes peroxisomal β-oxidation. Thus, the Pex1-G844D mouse provides a powerful model system for testing candidate therapies that address the most common genetic cause of ZSD. In addition, this murine model will enhance studies focused on mechanisms of pathogenesis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bile acids; PEX1; Peroxisome; Photoreceptor degeneration; Retinopathy; Zellweger spectrum disorder

Mesh:

Substances:

Year:  2014        PMID: 24503136      PMCID: PMC4901203          DOI: 10.1016/j.ymgme.2014.01.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  62 in total

Review 1.  Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking.

Authors:  David H Perlmutter
Journal:  Pediatr Res       Date:  2002-12       Impact factor: 3.756

2.  Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder.

Authors:  Merel S Ebberink; Petra A W Mooijer; Jeannette Gootjes; Janet Koster; Ronald J A Wanders; Hans R Waterham
Journal:  Hum Mutat       Date:  2011-01       Impact factor: 4.878

3.  Rapid and quantitative analysis of unconjugated C(27) bile acids in plasma and blood samples by tandem mass spectrometry.

Authors:  D W Johnson; H J ten Brink; R C Schuit; C Jakobs
Journal:  J Lipid Res       Date:  2001-01       Impact factor: 5.922

4.  Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds.

Authors:  Rui Zhang; Li Chen; Sarn Jiralerspong; Ann Snowden; Steven Steinberg; Nancy Braverman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

5.  Identification of a common PEX1 mutation in Zellweger syndrome.

Authors:  C S Collins; S J Gould
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

6.  A mouse model for Zellweger syndrome.

Authors:  M Baes; P Gressens; E Baumgart; P Carmeliet; M Casteels; M Fransen; P Evrard; D Fahimi; P E Declercq; D Collen; P P van Veldhoven; G P Mannaerts
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

7.  Disorders of peroxisome biogenesis due to mutations in PEX1: phenotypes and PEX1 protein levels.

Authors:  C Walter; J Gootjes; P A Mooijer; H Portsteffen; C Klein; H R Waterham; P G Barth; J T Epplen; W H Kunau; R J Wanders; G Dodt
Journal:  Am J Hum Genet       Date:  2001-06-01       Impact factor: 11.025

8.  Pex13 inactivation in the mouse disrupts peroxisome biogenesis and leads to a Zellweger syndrome phenotype.

Authors:  Megan Maxwell; Jonas Bjorkman; Tam Nguyen; Peter Sharp; John Finnie; Carol Paterson; Ian Tonks; Barbara C Paton; Graham F Kay; Denis I Crane
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

9.  A PEX10 defect in a patient with no detectable defect in peroxisome assembly or metabolism in cultured fibroblasts.

Authors:  S J Steinberg; A Snowden; N E Braverman; L Chen; P A Watkins; P T Clayton; K D R Setchell; J E Heubi; G V Raymond; A B Moser; H W Moser
Journal:  J Inherit Metab Dis       Date:  2008-12-25       Impact factor: 4.982

10.  Investigational methods for peroxisomal disorders.

Authors:  Steven Steinberg; Richard Jones; Carol Tiffany; Ann Moser
Journal:  Curr Protoc Hum Genet       Date:  2008-07
View more
  19 in total

Review 1.  Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines.

Authors:  Nancy E Braverman; Gerald V Raymond; William B Rizzo; Ann B Moser; Mark E Wilkinson; Edwin M Stone; Steven J Steinberg; Michael F Wangler; Eric T Rush; Joseph G Hacia; Mousumi Bose
Journal:  Mol Genet Metab       Date:  2015-12-23       Impact factor: 4.797

Review 2.  Pexophagy in yeast and mammals: an update on mysteries.

Authors:  Tanja Eberhart; Werner J Kovacs
Journal:  Histochem Cell Biol       Date:  2018-09-21       Impact factor: 4.304

Review 3.  Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward.

Authors:  Jean Bennett
Journal:  Mol Ther       Date:  2017-04-05       Impact factor: 12.910

4.  Induced pluripotent stem cell models of Zellweger spectrum disorder show impaired peroxisome assembly and cell type-specific lipid abnormalities.

Authors:  Xiao-Ming Wang; Wing Yan Yik; Peilin Zhang; Wange Lu; Ning Huang; Bo Ram Kim; Darryl Shibata; Madison Zitting; Robert H Chow; Ann B Moser; Steven J Steinberg; Joseph G Hacia
Journal:  Stem Cell Res Ther       Date:  2015-08-29       Impact factor: 6.832

Review 5.  Zellweger spectrum disorders: clinical overview and management approach.

Authors:  Femke C C Klouwer; Kevin Berendse; Sacha Ferdinandusse; Ronald J A Wanders; Marc Engelen; Bwee Tien Poll-The
Journal:  Orphanet J Rare Dis       Date:  2015-12-01       Impact factor: 4.123

Review 6.  Peroxisomes in brain development and function.

Authors:  Johannes Berger; Fabian Dorninger; Sonja Forss-Petter; Markus Kunze
Journal:  Biochim Biophys Acta       Date:  2015-12-11

7.  Ophthalmologic Findings in Patients with Neuro-metabolic Disorders.

Authors:  Narjes Jafari; Karl Golnik; Mansoor Shahriari; Parvaneh Karimzadeh; Sayena Jabbehdari
Journal:  J Ophthalmic Vis Res       Date:  2018 Jan-Mar

Review 8.  Mechanisms and Functions of Pexophagy in Mammalian Cells.

Authors:  Jing Li; Wei Wang
Journal:  Cells       Date:  2021-05-03       Impact factor: 6.600

Review 9.  Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss.

Authors:  Gayle B Collin; Navdeep Gogna; Bo Chang; Nattaya Damkham; Jai Pinkney; Lillian F Hyde; Lisa Stone; Jürgen K Naggert; Patsy M Nishina; Mark P Krebs
Journal:  Cells       Date:  2020-04-10       Impact factor: 7.666

10.  Zellweger spectrum disorders: clinical manifestations in patients surviving into adulthood.

Authors:  Kevin Berendse; Marc Engelen; Sacha Ferdinandusse; Charles B L M Majoie; Hans R Waterham; Frédéric M Vaz; Johannes H T M Koelman; Peter G Barth; Ronald J A Wanders; Bwee Tien Poll-The
Journal:  J Inherit Metab Dis       Date:  2015-08-19       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.